Impact of Eszopiclone on Blood Pressure in Patients With Insomnia and Hypertension (PRYSMA-HTN)

PHASE4RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

December 31, 2026

Conditions
InsomniaHypertension
Interventions
DRUG

Eszopiclone 3 mg

Eszopiclone is an FDA-approved treatment for insomnia in those who have difficulty falling asleep and for patients with difficulty staying asleep (sleep maintenance).

DRUG

Placebo

Placebo pills identical to the active comparator.

Trial Locations (1)

05403900

RECRUITING

Academic Research Organization - Heart Institute (InCor), São Paulo

Sponsors
All Listed Sponsors
collaborator

Eurofarma Laboratorios S.A.

INDUSTRY

lead

University of Sao Paulo

OTHER